Page last updated: 2024-11-06

danofloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Danofloxacin is a synthetic fluoroquinolone antibiotic that is used to treat bacterial infections in animals. It is bactericidal, meaning that it kills bacteria. Danofloxacin works by inhibiting the activity of bacterial DNA gyrase, an enzyme that is essential for bacterial DNA replication. This inhibition prevents the bacteria from replicating and ultimately leads to their death. Danofloxacin is effective against a wide range of gram-negative and gram-positive bacteria, including Escherichia coli, Salmonella spp., Staphylococcus aureus, and Pasteurella multocida. It is commonly used to treat respiratory infections, skin infections, urinary tract infections, and other infections in cattle, pigs, poultry, and horses. Danofloxacin is also used to treat bacterial infections in fish. Danofloxacin is typically administered orally or by injection. It is available in a variety of formulations, including tablets, capsules, oral solutions, and injectable solutions. Danofloxacin is generally well tolerated by animals, but side effects can occur. The most common side effects are gastrointestinal disturbances, such as vomiting, diarrhea, and anorexia. Danofloxacin can also cause hypersensitivity reactions in some animals. Danofloxacin is a valuable tool for treating bacterial infections in animals. It is an effective and safe antibiotic that is widely used in veterinary medicine. Danofloxacin is studied to better understand its effects on bacteria, to develop new and improved formulations of the drug, and to explore its potential use in humans. '

Cross-References

ID SourceID
PubMed CID71335
CHEMBL ID157548
CHEBI ID183837
SCHEMBL ID149627
MeSH IDM0187500

Synonyms (61)

Synonym
danofloxacin
NCGC00164548-01
112398-08-0
advocin (tn)
a180 (tn)
danofloxacin (inn)
D07774
CHEMBL157548
CHEBI:183837
1-cyclopropyl-6-luoro-7-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-oxoquinoline-3-carboxylic acid
A802567
1-cyclopropyl-6-fluoro-7-((1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
cas-112398-08-0
dtxcid8026432
dtxsid0046432 ,
tox21_112177
smr003500744
MLS004774070
danofloxacine
danofloxacinum
danofloxacino
danofloxacinum [inn-latin]
3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-(5-methyl-2,5-diazabicyclo(2.2.1)hept-2-yl)-4-oxo-, (1s)-
danofloxacin [inn:ban]
unii-24cu1ys91d
24cu1ys91d ,
danofloxacino [inn-spanish]
danofloxacine [inn-french]
danofloxacin [mi]
1-cyclopropyl-6-fluoro-1,4-dihydro-7-((1s,4s)-5-methyl-2,5-diazabicyclo(2.2.1)hept-2-yl)-4-oxo-3-quinolinecarboxylic acid
danofloxacin [green book]
danofloxacin [inn]
A180 ,
SCHEMBL149627
NCGC00164548-02
tox21_112177_1
QMLVECGLEOSESV-RYUDHWBXSA-N
3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-7-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]-4-oxo-
AB01566811_01
mfcd00864910
sr-01000872586
SR-01000872586-1
danofloxacin, vetranal(tm), analytical standard
1-cyclopropyl-6-fluoro-7-[(1s,4s)-3-methyl-3,6-diazabicyclo[2.2.1]heptan-6-yl]-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-((1s,4s)-
5-methyl-2,5-diazabicyclo
[2.2.1]heptan-2-yl)-4-oxo-1,4-
Q5220980
DB11393
CS-W011833
danofloxacin 100 microg/ml in acetonitrile
AKOS016844311
HY-W011117
F87699
danofloxacino (inn-spanish)
1-cyclopropyl-6-fluoro-7-((1s,4s)-3-methyl-3,6-diazabicyclo(2.2.1)heptan-6-yl)-4-oxoquinoline-3-carboxylic acid
danofloxacinum (inn-latin)
danofloxacine (inn-french)
advocin sterile injectable solution
EN300-19651949
1-cyclopropyl-6-fluoro-7-[(1s,4s)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

Research Excerpts

Overview

Danofloxacin is an antibacterial drug of the fluoroquinolone group developed for therapeutic purposes in veterinary medicine. It is used to treat and control bovine respiratory disease caused by Mannheimia haemolytica or Pasteurella multocida.

ExcerptReferenceRelevance
"Danofloxacin is a synthetic fluoroquinolone with broad spectrum antibacterial activity that is used for the treatment of respiratory diseases in animal husbandry. "( In vitro selection of RNA aptamers that selectively bind danofloxacin.
Han, SR; Lee, SW; Yu, J, 2014
)
2.09
"Danofloxacin is an antibacterial drug of the fluoroquinolone group developed for therapeutic purposes in veterinary medicine. "( Residue Depletion Study of Danofloxacin in Cultured Tilapia (Oreochromis mossambicus).
Chang, MH; Chen, PH; Fan, YC; Kuo, TF; Lai, HT; Lei, YC; Sheu, SY; Wang, CY,
)
1.87
"Danofloxacin is a fluoroquinolone antibacterial agent approved for use in veterinary medicine to treat and control bovine respiratory disease caused by Mannheimia haemolytica or Pasteurella multocida. "( New interpretive criteria for danofloxacin antibacterial susceptibility testing against Mannheimia haemolytica and Pasteurella multocida associated with bovine respiratory disease.
Papich, MG; Sweeney, MT; Watts, JL, 2017
)
2.19
"Danofloxacin is a fluoroquinolone developed for use in veterinary medicine. "( Concentrations of danofloxacin 18% solution in plasma, milk and tissues after subcutaneous injection in dairy cows.
Errecalde, J; Marchetti, ML; Mestorino, N; Pesoa, J; Turic, E, 2009
)
2.13
"Danofloxacin is a synthetic fluoroquinolone antibacterial agent and a substrate for ATP-binding cassette transporter G2/breast cancer resistance protein (ABCG2/BCRP). "( Inhibition of ABCG2/BCRP transporter by soy isoflavones genistein and daidzein: effect on plasma and milk levels of danofloxacin in sheep.
Alvarez, AI; Barrera, B; Merino, G; Otero, JA; Perez, M; Prieto, JG, 2013
)
2.04
"Danofloxacin is a fluoroquinolone developed for veterinary medicine showing an excellent activity. "( Pharmacokinetics of danofloxacin in horses after intravenous, intramuscular and intragastric administration.
Ayala, I; Cárceles, CM; Carrión, A; Escudero, E; Fernández-Varón, E; Marín, P; Martos, N, 2006
)
2.1
"Danofloxacin is a new synthetic fluoroquinolone antibacterial agent under development for exclusive use in veterinary medicine. "( Microbial models of soil metabolism: biotransformations of danofloxacin.
Chang, HY; Chen, Y; Kiplinger, JP; Nowakowski, MA; Reese, CP; Rosazza, JP,
)
1.82
"Danofloxacin is a new fluoroquinolone antibacterial, developed specifically for veterinary use. "( Clinical pharmacokinetics of parenterally administered danofloxacin in cattle.
Giles, CJ; Grimshaw, WT; Lynch, MJ; Magonigle, RA; Rice, JR; Risk, JE; Tanner, AC, 1991
)
1.97

Treatment

Danofloxacin treatment resulted in a significant up-regulation of the measured transporters at the transcriptional level in the upper part of gastro-intestinal tract, liver and kidneys as well as in barrier-protected organs, such as the brain. Treatment with danofl Oxacin and tylosin significantly decreased mortality and increased weight gain compared with infected unmedicated birds.

ExcerptReferenceRelevance
"Danofloxacin treatment consistently resulted in the Euryarchaeota phyla decreasing over time, specifically due to a decrease in Methanobrevibacter."( Effects of danofloxacin dosing regimen on gastrointestinal pharmacokinetics and fecal microbiome in steers.
Callahan, BJ; Foster, DM; Halleran, JL; Jacob, ME; Papich, MG; Prange, T; Sylvester, HJ, 2021
)
1.73
"Danofloxacin treatment resulted in a significant up-regulation of the measured transporters at the transcriptional level in the upper part of gastro-intestinal tract, liver and kidneys as well as in barrier-protected organs, such as the brain."( Expression of MDR1, MRP2 and BCRP mRNA in tissues of turkeys.
Fink-Gremmels, J; Haritova, AM; Lashev, LD; Schrickx, J, 2008
)
1.07
"Danofloxacin-treated cows showed statistically significant lower local clinical scores and a more rapid return to pre-inoculation values."( Evaluation of the efficacy of systemic danofloxacin in the treatment of induced acute Escherichia coli bovine mastitis.
Payne-Johnson, M; Pothier, F; Poutrel, B; Roy, O; Stegemann, MR; Tilt, N, 2008
)
1.34
"Danofloxacin-treated (n=12, group A) and control pigs (n=15, group B) were subsequently treated with tylosin and sampled longitudinally."( Longitudinal on-farm study of the development of antimicrobial resistance in Campylobacter coli from pigs before and after danofloxacin and tylosin treatments.
Hänninen, ML; Juntunen, P; Olkkola, S, 2011
)
1.3
"All danofloxacin-treated goats showed resolution of clinical disease by the end of the trial."( Effect of danofloxacin (Advocin A180) on goats affected with contagious caprine pleuropneumonia.
Ayling, RD; Churchward, C; Godinho, KS; Loria, GR; Nicholas, RA; Ozdemir, U; Rowan, TG; Samson, R,
)
1.01
"Treatment with danofloxacin and tylosin significantly decreased mortality and increased weight gain compared with infected unmedicated birds."( Efficacy of danofloxacin in the therapy of experimental mycoplasmosis in chicks.
Bennejean, G; Cooper, AC; Gesbert, F; Guittet, M; Kempf, I, 1992
)
1

Pharmacokinetics

The pharmacodynamic effect of amoxicillin and danofloxacin against two strains of Salmonella typhimurium was examined in an in-vitro pharmacodynamic model. Pharmacokinetic parameter values for both application routes calculated by noncompartmental methods were similar to enrofloxacins.

ExcerptReferenceRelevance
" Its in vitro activity and pharmacokinetic properties have been investigated to assess its potential for use in the therapy of respiratory disease in cattle."( Clinical pharmacokinetics of parenterally administered danofloxacin in cattle.
Giles, CJ; Grimshaw, WT; Lynch, MJ; Magonigle, RA; Rice, JR; Risk, JE; Tanner, AC, 1991
)
0.53
"The pharmacodynamic effect of amoxycillin and danofloxacin against two strains of Actinobacillus pleuropneumoniae was evaluated in an in-vitro pharmacodynamic model."( The pharmacodynamic effect of amoxycillin and danofloxacin against Actinobacillus pleuropneumoniae in an in-vitro pharmacodynamic model.
Friis, C; Jensen, NE; Lindecrona, RH, 1999
)
0.82
"The pharmacodynamic effect of amoxicillin and danofloxacin against two strains of Salmonella typhimurium was examined in an in-vitro pharmacodynamic model."( The pharmacodynamic effect of amoxicillin and danofloxacin against Salmonella typhimurium in an in-vitro pharmacodynamic model.
Aarestrup, FM; Friis, C; Lindecrona, RH, 2000
)
0.82
" Pharmacokinetic and pharmacodynamic data were integrated to determine the ratio of the area under the concentration versus time curve to the minimum inhibitory concentration of danofloxacin (AUIC)."( Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration.
Aliabadi, FS; Lees, P, 2001
)
0.77
"Integration of danofloxacin pharmacokinetic and pharmacodynamic data obtained in goats may provide a new approach on which to base recommendations for therapeutic dosages."( Pharmacokinetics and pharmacodynamics of danofloxacin in serum and tissue fluids of goats following intravenous and intramuscular administration.
Aliabadi, FS; Lees, P, 2001
)
0.93
" The pharmacokinetic properties of danofloxacin in serum, inflamed tissue cage fluid (exudate), and noninflamed tissue cage fluid (transudate) were established by using a tissue cage model."( Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids.
Aliabadi, FS; Landoni, MF; Lees, P, 2003
)
0.83
" Minimal inhibitory concentrations (MICs) assay of danofloxacin against 30 strains of Staphylococcus aureus from several European countries was performed in order to compute pharmacodynamic surrogate markers."( Pharmacokinetic-pharmacodynamic integration of danofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits.
Cárceles, CM; Escudero, E; Fernández-Varón, E; Marin, P; Vancraeynest, D, 2007
)
0.85
"The purpose of this study was to examine the allometric analyses of marbofloxacin, moxifloxacin, danofloxacin and difloxacin using pharmacokinetic data from the literature."( Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis.
Cox, SK, 2007
)
0.81
" Danofloxacin shows a favourable pharmacokinetic profile in loggerhead turtles reflected by parameters such as a long half-life and a high bioavailability following a single dose of 6 mg kg(-1) by IM and SC routes; thus, it is likely that this treatment will be effective in loggerhead turtles with bacterial infections."( Pharmacokinetics of danofloxacin after single dose intravenous, intramuscular and subcutaneous administration to loggerhead turtles Caretta caretta.
Almela, R; Bayón, A; Cárceles, CM; Clavel, C; Escudero, E; Fernández-Varón, E; Marín, P, 2008
)
1.58
"A population approach was used to evaluate the pharmacokinetic parameters of 3 fluoroquinolones administered to Japanese quail (Coturnix coturnix japonica)."( Comparative pharmacokinetics of enrofloxacin, danofloxacin, and marbofloxacin after intravenous and oral administration in Japanese quail (Coturnix coturnix japonica).
Dimitrova, D; Dinev, T; Haritova, A; Lashev, L; Moutafchieva, R, 2013
)
0.65
" The values of the pharmacokinetic parameters after both applications were calculated on the basis of a one-compartment model."( Comparative pharmacokinetics of danofloxacin in common pheasants, guinea fowls and Japanese quails after intravenous and oral administration.
Dimitrova, DJ; Dinev, TD; Haritova, AM; Lashev, LD; Moutafchieva, RG, 2014
)
0.69
" Plasma and tissue drug concentrations were determined by liquid chromatography-tandem mass spectrometry, and noncompartmental pharmacokinetic analyses were performed."( Pharmacokinetics of danofloxacin following intramuscular administration of a single dose in koi (
Byrne, BA; Knych, HK; Parker-Graham, CA; Siniard, WC; Soto, E, 2020
)
0.88
"7 ng/mL) was reached approximately 45 minutes after danofloxacin administration; plasma elimination half-life was 15 hours."( Pharmacokinetics of danofloxacin following intramuscular administration of a single dose in koi (
Byrne, BA; Knych, HK; Parker-Graham, CA; Siniard, WC; Soto, E, 2020
)
1.13
" The pharmacokinetic characteristics of danofloxacin are usually explored in healthy animals, while those in endotoxemic broilers are still rare."( Influence of Escherichia coli endotoxemia on danofloxacin pharmacokinetics in broilers following single oral administration.
Ma, YB; Shao, HT; Song, ZW; Wang, H; Yang, F; Zhang, M, 2022
)
1.25

Bioavailability

Danofloxacin shows a favourable pharmacokinetic profile in loggerhead turtles reflected by parameters such as a long half-life and a high bioavailability following a single dose of 6 mg kg(-1) by IM and SC routes. It is likely that this treatment will be effective in loggerheads with bacterial infections.

ExcerptReferenceRelevance
" Danofloxacin was rapidly absorbed following intramuscular and subcutaneous injection and bioavailability was virtually complete (101% and 94% respectively)."( Clinical pharmacokinetics of parenterally administered danofloxacin in cattle.
Giles, CJ; Grimshaw, WT; Lynch, MJ; Magonigle, RA; Rice, JR; Risk, JE; Tanner, AC, 1991
)
1.44
" Bioavailability was 91%."( Lung tissue concentrations and plasma pharmacokinetics of danofloxacin in calves with acute pneumonia.
Apley, MD; Upson, DW, 1993
)
0.53
" Danofloxacin had an absolute bioavailability (F) of 95."( Pharmacokinetics and tissue disposition of danofloxacin in sheep.
Gibson, IF; McCormack, RZ; McKellar, QA, 1998
)
1.47
" injection but a 'flip flop' effect was clearly evident and bioavailability was > 100%."( Pharmacokinetics and penetration of danofloxacin from the blood into the milk of cows.
Glickman, A; Lavi, E; Rav-Hon, O; Saran, A; Shem-Tov, M; Ziv, G, 1998
)
0.58
" Bioavailability (F) was high: 99% for danofloxacin and 89% for enrofloxacin."( Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens.
Glünder, G; Kietzmann, M; Knoll, U, 1999
)
0.8
" The systemic bioavailability after IM injection was 65."( Some pharmacokinetic data for danofloxacin in healthy goats.
Abd El-Aty, AM; Amer, MM; Atef, M; El-Gendi, AY, 2001
)
0.6
" After oral administration, the values of the absolute bioavailability and the elimination half-life were 78."( Pharmacokinetic-pharmacodynamic modelling of danofloxacin in turkeys.
Fink-Gremmels, J; Haritova, AM; Lashev, LD; Parvanov, PR; Rusenova, NV, 2006
)
0.59
" administration, the absolute bioavailability was mean (+/-SD) 102."( Pharmacokinetic-pharmacodynamic integration of danofloxacin after intravenous, intramuscular and subcutaneous administration to rabbits.
Cárceles, CM; Escudero, E; Fernández-Varón, E; Marin, P; Vancraeynest, D, 2007
)
0.6
" Danofloxacin had an absolute bioavailability of 93."( Pharmacokinetics of danofloxacin 18% in lactating sheep and goats.
Benchaoui, H; Cárceles, CM; Escudero, E; Fernandez-varon, E; Marin, P, 2007
)
1.57
" Danofloxacin shows a favourable pharmacokinetic profile in loggerhead turtles reflected by parameters such as a long half-life and a high bioavailability following a single dose of 6 mg kg(-1) by IM and SC routes; thus, it is likely that this treatment will be effective in loggerhead turtles with bacterial infections."( Pharmacokinetics of danofloxacin after single dose intravenous, intramuscular and subcutaneous administration to loggerhead turtles Caretta caretta.
Almela, R; Bayón, A; Cárceles, CM; Clavel, C; Escudero, E; Fernández-Varón, E; Marín, P, 2008
)
1.58
" The highest bioavailability was observed for danofloxacin followed by marbofloxacin, while very low bioavailability with significant conversion to ciprofloxacin was observed for enrofloxacin."( Comparative pharmacokinetics of enrofloxacin, danofloxacin, and marbofloxacin after intravenous and oral administration in Japanese quail (Coturnix coturnix japonica).
Dimitrova, D; Dinev, T; Haritova, A; Lashev, L; Moutafchieva, R, 2013
)
0.91
" Oral bioavailability values were 82."( Comparative pharmacokinetics of danofloxacin in common pheasants, guinea fowls and Japanese quails after intravenous and oral administration.
Dimitrova, DJ; Dinev, TD; Haritova, AM; Lashev, LD; Moutafchieva, RG, 2014
)
0.69
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."( Highly predictive and interpretable models for PAMPA permeability.
Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" ABCG2 is an efflux protein involved in the bioavailability and milk secretion of drugs."( Role of eprinomectin as inhibitor of the ruminant ABCG2 transporter: Effects on plasma distribution of danofloxacin and meloxicam in sheep.
Alvarez, AI; Alvarez-Fernandez, I; Blanco-Paniagua, E; Garcia-Lino, AM; Garcia-Mateos, D; Medina, JM; Merino, G, 2021
)
0.84

Dosage Studied

The objective of this study was to determine the gastrointestinal pharmacokinetics and impact on enteric bacteria of cattle when receiving one of the two dosing regimens. The dosage regimens were designed with an expected difference in therapeutic efficacy in favour of danofloxacin.

ExcerptRelevanceReference
" This article proposes that dosage schedules should be developed to provide a basis for the rational use of antimicrobial drugs."( Antibiotic treatment for animals: effect on bacterial population and dosage regimen optimisation.
AliAbadi, FS; Lees, P, 2000
)
0.31
" Maximal pharmacodynamic effect was observed when the antibiotic concentration was greater than minimum inhibitory concentration for 79 per cent or more of the dosing interval."( The pharmacodynamic effect of amoxicillin and danofloxacin against Salmonella typhimurium in an in-vitro pharmacodynamic model.
Aarestrup, FM; Friis, C; Lindecrona, RH, 2000
)
0.57
" dosing and 55."( Pharmacokinetics (PK), pharmacodynamics (PD), and PK-PD integration of danofloxacin in sheep biological fluids.
Aliabadi, FS; Landoni, MF; Lees, P, 2003
)
0.55
") dosing absorption was complete (F=114."( Pharmacokinetics and PK-PD modelling of danofloxacin in camel serum and tissue cage fluids.
Ali, BH; Aliabadi, FS; Landoni, MF; Lees, P, 2003
)
0.59
" A novel approach to selecting antimicrobial drug dosage for evaluation in clinical trials, using AUC/MIC values producing either bactericidal activity or elimination of bacteria together with MIC(90) values for calf pathogens, is proposed."( Pharmacokinetic-pharmacodynamic integration of danofloxacin in the calf.
Lees, P; Shojaee Aliabadi, F, 2003
)
0.58
" To test the discriminative properties of the biomarkers, the dosage regimens were designed with an expected difference in therapeutic efficacy in favour of danofloxacin."( Putative biomarkers for evaluating antibiotic treatment: an experimental model of porcine Actinobacillus pleuropneumoniae infection.
Angen, Ø; Friis, C; Lauritzen, B; Lykkesfeldt, J; Nielsen, JP; Skaanild, MT, 2003
)
0.52
" These dosage regimens resulted in similar AUCs of the plasma danofloxacin vs time curve."( Evaluation of a single dose versus a divided dose regimen of danofloxacin in treatment of Actinobacillus pleuropneumoniae infection in pigs.
Friis, C; Lauritzen, B; Lykkesfeldt, J, 2003
)
0.8
"25 mg/kg to select the optimal dosage regimen of danofloxacin."( Pharmacokinetics, urinary excretion and plasma protein binding of danofloxacin following intravenous administration in buffalo calves (Bubalus bubalis).
Chaudhary, RK; Sandhu, HS; Sappal, R; Sidhu, PK, 2009
)
0.84
" Multiple dosing of administration was incorporated into the healthy and infected models."( Estimating danofloxacin withdrawal time in broiler chickens based on physiologically based pharmacokinetics modeling.
Liu, YM; Sun, N; Yang, F; Zeng, ZL, 2015
)
0.81
" gallisepticum was explored based on the available data obtained from various dosing regimens in the in vitro model."( Relationship between danofloxacin PK/PD parameters and emergence and mechanism of resistance of Mycoplasma gallisepticum in In Vitro model.
Cai, Q; Ding, H; Huang, Z; Jiang, H; Shen, X; Wu, Y; Zhang, C; Zhang, L; Zhang, N, 2018
)
0.8
" The objective of this study was to determine the gastrointestinal pharmacokinetics and impact on enteric bacteria of cattle when receiving one of the two dosing regimens (high: 40 mg/kg SC once or low: 20 mg/kg IM q48hr) of danofloxacin, a commonly utilized synthetic fluoroquinolone in veterinary medicine."( Effects of danofloxacin dosing regimen on gastrointestinal pharmacokinetics and fecal microbiome in steers.
Callahan, BJ; Foster, DM; Halleran, JL; Jacob, ME; Papich, MG; Prange, T; Sylvester, HJ, 2021
)
1.2
" While low toxicity, high bactericidal activity, and availability in single and multiple dosing regimens make them preferable, the increasing incidence of FQ-resistance in foodborne pathogens and effects on gut microbiota necessitate evaluating their pharmacokinetics (PKs)."( Comparisons of plasma and fecal pharmacokinetics of danofloxacin and enrofloxacin in healthy and Mannheimia haemolytica infected calves.
Beyi, AF; Coetzee, JF; Dewell, G; Dewell, R; Hawbecker, T; Magnin, G; Mochel, JP; Plummer, PJ; Sahin, O; Slagel, C; Zhang, Q, 2022
)
0.97
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.15770.006038.004119,952.5996AID1159523
TDP1 proteinHomo sapiens (human)Potency6.68380.000811.382244.6684AID686978; AID686979
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency11.57740.001530.607315,848.9004AID1259401
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (124)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (111)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1645848NCATS Kinetic Aqueous Solubility Profiling2019Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508591NCATS Rat Liver Microsome Stability Profiling2020Scientific reports, 11-26, Volume: 10, Issue:1
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508612NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling2017Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
Highly predictive and interpretable models for PAMPA permeability.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID155925In vivo protective dose was evaluated against Pasteurella multocida (59A006) in mouse(po)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID69987Escherichia coli DNA cleavage endpoint value which is the minimum amount required (in micro g/mL) to induce detectable cleavage of supercoiled pBR322 substrate to linear form (gyrase)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278266Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 acrAB::Kan with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278246Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID200497In vivo protective dose was evaluated against Salmonella choleraesuis (58B010) in mouse(sc)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278259Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID41564In vitro antibacterial activity against anaerobically grown Bacteroides vulgatus (78D029)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278239Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278249Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID155751Dose was evaluated for minimum effective dose Pasteurella haemolytica, intramuscular dose administration1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278251Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 tolC::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278236Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID70475In vivo protective dose was evaluated against Escherichia coli (51A266) in mouse(po)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID70476In vivo protective dose was evaluated against Escherichia coli (51A266) in mouse(sc)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID51018In vitro antibacterial activity against anaerobically grown Clostridium perfringens (10A009)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID210971In vitro evaluation for antibacterial activity against anaerobically grown Treponema hyodysenteriae (94A007)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278252Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID30568In vitro antibacterial activity against anaerobically grown Actinomyces pyogenes (14D002)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278242Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278261Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 gyrA+ with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278234Antimicrobial activity against Salmonella enterica serovar Typhimurium GyrA S21-1 acrAB::Kan with GyrA S83F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278233Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 gyrA+2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278240Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278260Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278254Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278255Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 tolC::Kan with GyrA S83F, D87N, parC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278257Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID155926In vivo protective dose was evaluated against Pasteurella multocida (59A006) in mouse(sc)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278247Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278248Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID515780Intrinsic solubility of the compound in water2010Bioorganic & medicinal chemistry, Oct-01, Volume: 18, Issue:19
QSAR-based solubility model for drug-like compounds.
AID278230Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 acrAB::Kan2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278253Antimicrobial activity against Salmonella enterica serovar Typhimurium CS3 gyrA+ with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID42650In vitro antibacterial activity against aerobically grown Bordetella bronchiseptica (73A009)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278269Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 gyrA+ with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID30554Compound was evaluated for minimum effective dose Actinobacillus pleuropneumonia, peroral dose administration1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278231Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 tolC::Kan2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278235Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 tolC::Kan with GyrA S83F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID155752Dose was evaluated for minimum effective dose actinobacillus pleuropneumonia, intramuscular dose administration1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278264Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278267Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 tolC::Kan with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID200496In vivo protective dose was evaluated against Salmonella choleraesuis (58B010) in mouse(po)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278265Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS18 gyrA+ with GyrA S38F mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278258Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278256Antimicrobial activity against Salmonella enterica serovar Typhimurium CS9 with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278243Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 tolC::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278268Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID155754In vitro antibacterial activity against Aerobically grown Pasteurella haemolytica (59B018)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID21119In vivo protective dose was evaluated for aqueous solubility at pH 7.21992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278245Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278229Antimicrobial activity against Salmonella enterica serovar Typhimurium S21 gyrA+2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID70479In vitro antibacterial activity against aerobically grown Escherichia coli (51A538)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278262Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 acrAB::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID30557In vitro antibacterial activity against anaerobically grown Actinobacillus pleuropneumoniae (54B004)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278271Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 tolC::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278263Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS14 tolC::Kan with GyrA D87G mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278238Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 acrAB::Kan with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278244Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-4 with GyrA S83F, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278237Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-2 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278228Antimicrobial activity against Salmonella enterica serovar Typhimurium S212007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278241Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-3 gyrA+ with ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID155922In vitro antibacterial activity against aerobically grown Pasteurella multocida (59A006)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID207257In vitro antibacterial activity against aerobically grown Staphylococcus aureus (54B004)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID278270Antimicrobial activity against Salmonella enterica serovar Typhimurium CHS38 acrAB::Kan with GyrA D87G mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278232Antimicrobial activity against Salmonella enterica serovar Typhimurium S21-1 GyrA S83F mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID278250Antimicrobial activity against Salmonella enterica serovar Typhimurium CS1 acrAB::Kan with GyrA S83F, D87N, ParC S80I mutation2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Contribution of target gene mutations and efflux to decreased susceptibility of Salmonella enterica serovar typhimurium to fluoroquinolones and other antimicrobials.
AID200499In vitro antibacterial activity against aerobically grown Salmonella choleraesuis (58B015)1992Journal of medicinal chemistry, Feb-21, Volume: 35, Issue:4
Synthesis and structure-activity relationships of 7-diazabicycloalkylquinolones, including danofloxacin, a new quinolone antibacterial agent for veterinary medicine.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (175)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's26 (14.86)18.2507
2000's59 (33.71)29.6817
2010's66 (37.71)24.3611
2020's24 (13.71)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.93 (24.57)
Research Supply Index5.33 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index67.14 (26.88)
Search Engine Supply Index2.06 (0.95)

This Compound (42.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (10.22%)5.53%
Reviews1 (0.54%)6.00%
Case Studies1 (0.54%)4.05%
Observational0 (0.00%)0.25%
Other165 (88.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]